Related Experiment Video
Updated: Nov 10, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
Ingrid Fricke-Galindo1, Ramcés Falfán-Valencia1
1HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.
Abstract:
The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. We aimed to describe the pharmacogenetic variants reported for drugs used for COVID-19 treatment (remdesivir, oseltamivir, lopinavir, ritonavir, azithromycin, chloroquine, hydroxychloroquine, ivermectin, and dexamethasone). In addition, other factors relevant to the design of pharmacogenetic studies were mentioned. Variants in CYP3A4, CYP3A5, CYP2C8, CY2D6, ABCB1, ABCC2, and SLCO1B1, among other variants, could be included in pharmacogenetic studies of COVID-19 treatment. Besides, nongenetic factors such as drug-drug interactions and inflammation should be considered in the search for personalized therapy of COVID-19.
More Related Videos
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Single Nucleotide Polymorphisms-SNPs
Factors Affecting Drug Response: Overview
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Measurement of Bioavailability: Pharmacodynamic Methods
Microorganisms in Medicine and Therapeutics

